913645-28-0

Upstream product

• 1186016-68-1 C₁₆H₂₄N₂O₂ 
• 505-66-8 1,4-Diazacycloheptane 
• 105-36-2 ethyl bromoacetate 
• 105-39-5 chloroacetic acid ethyl ester 

Downstream Products

• 913643-59-1 (4-{3-[(R)-((2S,5R)-4-allyl-2,5-dimethyl-piperazin-1-yl)-(3-hydroxy-phenyl)-methyl]-benzoyl}-[1,4]diazepan-1-yl)-acetic acid ethyl ester 

Relevant academic research and scientific papers

For the treatment of a keratitis active pharmaceutical and its preparation method

The invention relates to an active drug for treating keratitis. The active drug has a structure shown as a formula I. Test results show that whether the drug is applied beforehand or afterwards or not, the active drug has an obvious inhibition effect on inflammatory chemokine increase caused by the keratitis, which shows that the active drug also has good prevention and treatment effects on the keratitis, thereby being suitable for treating the keratitis.

CHIRAL CIS-IMIDAZOLINES

There are provided compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein X, Y, Z, V1, V2, R1, R2, R3, R4 and R5 are as herein described, processes for obtaining said compounds and pharmaceutical preparations containing them. These compounds are useful as anticancer agents, in particular as agents in the treatment of solid tumors.

COMPOSITIONS OF NOVEL OPIOID COMPOUNDS AND METHOD OF USE THEREOF

Diarylmethylpiperazine compounds are described, which are useful as mu and/or delta receptor opioid compounds, without central side effects. Pharmaceutical compositions containing such compounds are variously useful for peripheral or non-centrally mediated indications, including peripherally mediated and neuropathic pain, urogenital tract disorders, overactive bladder, urinary incontinence, sexual disorders, premature ejaculation, cough, lung edema, cardiac disorders, cardioprotection, gastro-intestinal disorders, diarrhea, irritable bowl syndrome, functional distention, immuno-modulation and anti-tumor activity.

4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases

The present invention relates to bicyclic heterocycles of general formula wherein Ra to Rd, A to G and X are defined as in claim 1, the tautomers, the steroisomers and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids or bases which have valuable pharmacological properties, particularly an inhibiting effect on signal transduction mediated by tyrosine kinases, their use for treating diseases, particularly tumoral diseases, diseases of the lungs and respiratory tract, and the preparation thereof.